Identification of Centrosome Duplication‐Related Biomarkers in Hypertrophic Cardiomyopathy Through Integrative Multi‐Omics, Single‐Cell Transcriptomics, and Experimental Validation Authors: Huigan Li, Weihua Liu, Xun Huang, Zhigang You, Lin Huang Published: 2026 ABSTRACT BackgroundHypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiovascular disorder characterized by ventricular wall thickening and myocardial fibrosis. Centrosome duplication‐related gene play critical roles in cell cycle regulation, microtubule organization, and cellular structural homeostasis; however, their mechanistic involvement in HCM remains unclear.MethodsAn integrative multi‐omics strategy was used, incorporating differential expression analysis, weighted gene co‐expression network analysis, Mendelian randomization), and multiple machine‐learning models to identify centrosome duplication‐related genes associated with HCM. Single‐cell RNA sequencing was used to assess cell‐type‐specific expression patterns, followed by in vitro functional assays in cardiomyocytes.ResultsTwo candidate biomarkers, HBEGF and VPS8, were significantly associated with HCM across multiple data sets. Single‐cell transcriptomic analysis revealed high VPS8 expression in cardiomyocytes and dendritic cells. Functional assays show that VPS8 knockdown suppressed cardiomyocyte proliferation, increased apoptosis, and reduced the expression of proteins involved in centrosome and microtubule organization, suggesting its involvement in structural maintenance and cell cycle regulation.ConclusionsThis study suggests a potential association between centrosome duplication‐related gene dysregulation and HCM pathogenesis and identifies VPS8 as a key regulator bridging endosomal–lysosomal homeostasis and immune‐related remodeling. VPS8 may represent a candidate biomarker and a potential therapeutic target for early diagnosis and intervention in HCM. Nonstandard Abbreviations and Acronyms Artificial Neural Network biological process centrosome duplication‐related genes differentially expressed genes epidermal growth factor receptor Gene Ontology Genome‐Wide Association Study heparin‐binding EGF‐like growth factor hypertrophic cardiomyopathy instrumental variables Mendelian randomization principal component analysis propidium iodide quality control RNA sequencing single‐cell RNA sequencing short hairpin RNA shRNA targeting VPS8 uniform manifold approximation and projection vacuolar protein sorting 8 homolog Weighted Gene Coexpression Network Analysis Clinical PerspectiveWhat Is New? By integrating multi‐database analysis, Mendelian randomization validation, and in vitro functional experiments, we first identified that centrosome duplication‐related genes HBEGF and VPS8 are specifically upregulated in hypertrophic cardiomyopathy, and VPS8 affects cardiomyocyte proliferation and apoptosis by regulating centrosomal proteins such as γ‐tubulin, which can serve as potential diagnostic biomarkers for hypertrophic cardiomyopathy. What Are the Clinical Implications? HBEGF and VPS8 provide non‐invasive and highly specific novel diagnostic targets for hypertrophic cardiomyopathy, and their mediated regulatory mechanism of centrosome duplication offers a new direction for the development of precision therapeutic drugs for hypertrophic cardiomyopathy, facilitating the improvement of clinical early diagnosis and treatment decisions. Clinical Perspective What Is New? By integrating multi‐database analysis, Mendelian randomization validation, and in vitro functional experiments, we first identified that centrosome duplication‐related genes HBEGF and VPS8 are specifically upregulated in hypertrophic cardiomyopathy, and VPS8 affects cardiomyocyte proliferation and apoptosis by regulating centrosomal proteins such as γ‐tubulin, which can serve as potential diagnostic biomarkers for hypertrophic cardiomyopathy. By integrating multi‐database analysis, Mendelian randomization validation, and in vitro functional experiments, we first identified that centrosome duplication‐related genes HBEGF and VPS8 are specifically upregulated in hypertrophic cardiomyopathy, and VPS8 affects cardiomyocyte proliferation and apoptosis by regulating centrosomal proteins such as γ‐tubulin, which can serve as potential diagnostic biomarkers for hypertrophic cardiomyopathy. By integrating multi‐database analysis, Mendelian randomization validation, and in vitro functional experiments, we first identified that centrosome duplication‐related genes HBEGF and VPS8 are specifically upregulated in hypertrophic cardiomyopathy, and VPS8 affects cardiomyocyte proliferation and apoptosis by regulating centrosomal proteins such as γ‐tubulin, which can serve as potential diagnostic biomarkers for hypertrophic cardiomyopathy. What Are the Clinical Implications? HBEGF and VPS8 provide non‐invasive and highly specific novel diagnostic targets for hypertrophic cardiomyopathy, and their mediated regulatory mechanism of centrosome duplication offers a new direction for the development of precision therapeutic drugs for hypertrophic cardiomyopathy, facilitating the improvement of clinical early diagnosis and treatment decisions. HBEGF and VPS8 provide non‐invasive and highly specific novel diagnostic targets for hypertrophic cardiomyopathy, and their mediated regulatory mechanism of centrosome duplication offers a new direction for the development of precision therapeutic drugs for hypertrophic cardiomyopathy, facilitating the improvement of clinical early diagnosis and treatment decisions. HBEGF and VPS8 provide non‐invasive and highly specific novel diagnostic targets for hypertrophic cardiomyopathy, and their mediated regulatory mechanism of centrosome duplication offers a new direction for the development of precision therapeutic drugs for hypertrophic cardiomyopathy, facilitating the improvement of clinical early diagnosis and treatment decisions. Hypertrophic cardiomyopathy (HCM) is a hereditary cardiac disorder characterized by ventricular wall hypertrophy, narrowing of the ventricular chamber, impaired left ventricular filling, and reduced diastolic compliance. 1 , 2 , 3 The disease has a high global incidence rate and significant familial clustering. Current evidence suggests that mutations in pathogenic genes of HCM lead to changes in the structure and function of myosin, which is the primary molecular genetic basis of the disease. 3 These changes can impair cardiac function, resulting in symptoms such as difficulty breathing, fatigue, chest pain, and fainting. In severe cases, HCM may progress to heart failure and sudden death. Currently, no curative therapy exists for HCM, and management is mainly symptomatic, focusing on alleviating symptoms, preventing complications, and improving patients' quality of life. However, patients remain at risk for worsening symptoms, continuous deterioration of heart function, and the occurrence of complications. 4 , 5 Therefore, identifying more effective treatment methods to improve the quality of life and therapeutic effects of patients with HCM has become a major focus in cardiovascular research. Within this framework, identifying biomarkers associated with HCM may provide an essential reference for refining treatment strategies. The centrosome is a membraneless organelle composed of multiple proteins, primarily responsible for organizing microtubules and establishing cell division polarity. It functions as the core microtubule‐organizing structure within cells. 6 , 7 Existing research has confirmed that abnormal centrosome replication or dysfunction is closely associated with the occurrence and development of various major diseases, such as cancer, neurodegenerative disorders, and cardiovascular conditions. 8 , 9 , 10 Within the cardiovascular system, centrosomes in cardiomyocytes not only contribute to the assembly and maintenance of the cytoskeleton but also influence cardiomyocyte proliferation and differentiation. 6 , 11 Studies have shown that impaired centrosome reorganization may underlie infantile dilated cardiomyopathy, and preliminary centrosome‐targeted therapeutic strategies for this condition have been identified. 12 However, the specific biological functions and molecular mechanisms of centrosome duplication‐related genes (CDRGs) in HCM remain largely unexplored, and research in this area is relatively scarce. Therefore, an in‐depth exploration of the biological roles and molecular mechanisms of CDRGs in HCM is critical for understanding disease pathogenesis and identifying potential new treatment strategies. RNA sequencing (RNA‐seq) allows for comprehensive profiling of gene transcription within cells or tissues, revealing the molecular mechanisms underlying disease onset and progression. 13 , 14 Mendelian randomization (MR) leverages genetic variants, particularly single‐nucleotide polymorphisms (SNPs), as instrumental variables (IVs) to infer potential causal relationships between exposures and outcomes. The validity of MR is based on the following 3 core assumptions: (1) the IVs must be closely associated with the exposure, (2) must be independent of potential confounders, and (3) must influence outcomes solely through the exposure factors. 15 Single‐cell RNA sequencing (scRNA‐seq) enables precise measurement of gene expression at the individual cell level, facilitating the analysis of cellular heterogeneity and revealing differential expression patterns across distinct cell types or within the same cell type under varying conditions. 16 In HCM research, integrating RNA‐seq, MR, and scRNA‐seq provides a multilevel approach—from gene expression profiling to causal inference and, ultimately, to cellular heterogeneity—thereby offering a more comprehensive understanding of the molecular mechanisms underlying disease onset and progression. This study integrated transcriptomic and scRNA‐seq data from HCM from publicly available databases and applied multiple bioinformatics analyses, including MR, to systematically identify key biomarkers associated with centrosome duplication in HCM. Subsequent in vitro experiments confirmed that these biomarkers play crucial roles in regulating cardiomyocyte proliferation, apoptosis, and centrosome duplication. These findings enhance the mechanistic understanding of HCM pathogenesis, enable early diagnostic applications, and facilitate the exploration of novel therapeutic strategies. METHODS In accordance with the Transparency and Openness Promotion Guidelines, we provide the following statements regarding the availability of data, methods, and materials. Data availability: The transcriptomic data sets (GSE36961, GSE141910, GSE130036, GSE160997, GSE32453, and GSE174691) analyzed in this study are publicly accessible through the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/). CDRGs were retrieved from the Molecular Signatures Database (https://www.gsea‐msigdb.org/), and GWAS (Genome‐Wide Association Study) data were obtained from the MiBioGen (https://www.mibiogen.org/) and Integrative Epidemiology Unit OpenGWAS (https://gwas.mrcieu.ac.uk/) databases, all of which are publicly available. Method availability: Analytical procedures—including differential expression analysis, Weighted Gene Coexpression Network Analysis (WGCNA), MR, and machine‐learning modeling—are described in detail in the Materials and Methods section. The R code scripts used for data processing and statistical analyses are available from the corresponding author upon reasonable request. Materials availability: The H9c2 cell line used in this study is commercially available, and all reagents are specified in the Materials and Methods section; all materials are accessible to researchers to enable experimental replication. Ethics statement: All omics and GWAS data sets used in this study were obtained from open‐access databases. The original studies obtained Institutional Review Board approval and documented informed consent from participants. Secondary analysis of deidentified public data was therefore exempt from further ethical review. The H9c2 cell line was obtained from a commercial supplier. No in vivo animal experiments or human studies were conducted, and all in vitro procedures adhered to standard laboratory biosafety guidelines and ethical practices. Data Source Transcriptomic data sets GSE36961 (platform: GPL15389), GSE141910 (platform: GPL16791), GSE130036 (platform: GPL20795), GSE160997 (platform: GPL11154), GSE32453 (platform: GPL6104), and GSE174691 (platform: GPL21697) were obtained from the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/). GSE36961 served as the training set and comprised cardiac tissue samples from 106 patients with HCM and 39 normal controls. The validation sets included GSE141910, GSE130036, GSE160997, and GSE32453. Analysis of myocardial tissue samples in the validation sets yielded HCM‐to‐control ratios of 28:166 in GSE141910, 28:9 in GSE130036, 18:5 in GSE160997, and 8:5 in GSE32453. The scRNA‐seq data set GSE174691 contained nine cardiac tissue samples from patients with HCM. Furthermore, Gene Ontology (GO) biological processes associated with centrosome duplication and negative regulation were retrieved from Molecular Signatures Database (https://www.gsea‐msigdb.org/), yielding 76 CDRGs (Table S1). Differential Expression Analysis To identify differentially expressed genes (DEGs) between the HCM and control groups in the GSE36961 data set, the limma package (v3.54.0) 17 was applied with thresholds of |log2 fold change|>0.5 and uncorrected P<0.05. Considering the exploratory nature of this study and the subsequent multi‐layer validation strategy (including independent data sets, machine learning, and in vitro experiments), an uncorrected P value threshold was initially used to prioritize DEGs, which were then stringently filtered through downstream analyses to minimize false positives. Visualization of DEGs was conducted using volcano plots generated using the ggplot2 package (v3.4.1) 18 and heatmaps constructed with the ComplexHeatmap package (v2.14.0). 19 WGCNA The single‐sample gene set enrichment analysis, implemented using the GSVA package (v1.42.0), 20 was applied to compute the CDRG scores for all samples in the GSE36961 data set. Subsequently, the Wilcoxon rank‐sum test was used to assess differences in CDRG scores between the HCM and control groups (P<0.05). To identify the modular genes most strongly associated with CDRGs, WGCNA was conducted on HCM samples from GSE36961 using the WGCNA package (v1.70.3). 21 Following this, the samples were analyzed using clustering. A sample clustering tree was constructed, and outlier samples were excluded. To maximize the scale‐free topological fit of gene interactions, a soft threshold (power) was selected for constructing the coexpression network based on a scale‐free fit index (signed R 2) exceeding 0.85 and a mean connectivity approaching zero. The filtered expression matrix was used to construct the WGCNA network, with a minimum module size of 100 genes and a module‐merging threshold (merge cut height) set to 0.25. Coexpression modules were subsequently identified and visualized using hierarchical clustering. CDRG scores were treated as phenotypic traits, and Pearson correlation analysis was conducted to assess the correlation matrix between CDRG scores and coexpression modules (|correlation coefficients (cor)|>0.30, P<0.05). Genes exhibiting the strongest positive or negative correlations with CDRG scores within the relevant modules were identified as key module genes. Identification and Functional Analysis of Candidate Genes The intersection of DEGs and key module genes was implemented using the VennDiagram package (v1.7.1) 22 to identify candidate genes associated with CDRGs in HCM. Functional annotations of these candidate genes were subsequently performed using the clusterProfiler package (v4.2.2), 23 which facilitated GO and Kyoto Encyclopedia of Genes and Genomes enrichment analyses of the candidate genes, with P<0.05 considered statistically significant. The GO terms were ranked in ascending order of P values, and the top 5 significantly enriched pathways within the biological process (BP), cellular component, and molecular function categories were visualized using the enrichplot package (v1.18.3). 24 Similarly, significantly enriched Kyoto Encyclopedia of Genes and Genomes pathways were visualized using the GOplot package (v1.0.2). 25 To examine interactions among candidate genes at the protein level, a protein–protein interaction network was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (https://www.string‐db.org) with an interaction score greater than 0.15. The resulting protein–protein interaction network was visualized using Cytoscape software (v3.8.2). 26 Screening of IVs MR analysis is based on 3 core assumptions: (1) IVs are strongly associated with the exposure factors; (2) IVs are independent of confounding factors; and (3) IVs influence the outcome exclusively through exposure factors and not through alternative pathways. Expression quantitative trait loci (eQTL) data for candidate genes were obtained from the Integrative Epidemiology Unit OpenGWAS database (https://gwas.mrcieu.ac.uk/), which provides eQTL summary statistics derived from European‐ancestry populations, and were treated as exposure factors. Concurrently, the HCM‐related data set (ebi‐a‐GCST90018861) from the Integrative Epidemiology Unit OpenGWAS database, comprising 24 199 797 SNPs from 489 727 European samples (cases:controls=507:489220), was used as the outcome variable. Exposure factors were initially read, and IVs—including SNPs and insertion/deletion variants—were extracted using the extract_instruments function of the TwoSampleMR package (v0.56). 27 IVs significantly associated with exposure factors were selected using a threshold of P<5×10−6. To mitigate potential bias due to linkage disequilibrium, IVs (SNPs) with linkage disequilibrium were removed using the parameters clump=TRUE, r 2=0.001, and kb=10. The strength of the IVs was assessed using F‐statistic tests, calculated as follows: F=R2×n−k−1k×1−R2, where R 2 is the squared correlation coefficient between the IVs and the exposure factor, n is the sample size, and k is the number of IVs. IVs with F‐statistics below 10 were excluded from the analysis. Finally, the harmonise_data function of the TwoSampleMR package (v 0.56) was used to unify the effect alleles and effect sizes, thereby ensuring proper matching between exposure factors, IVs, and outcome data. MR Analysis Potential causal relationships between candidate genes and HCM were assessed using the mr function of the TwoSampleMR package (v0.56) with 5 complementary algorithms—MR Egger, 28 weighted median, 29 inverse variance weighted, 30 simple mode, 31 and weighted mode. 32 The inverse variance weighted method served as the primary method for evaluating the results. Candidate genes were considered causally associated with HCM if the inverse variance weighted results were significant (P<0.05). Candidate genes with odds ratio (OR)>1 were classified as risk factors for HCM, whereas those with OR<1 were regarded as protective factors for HCM. Furthermore, MR results were visualized using scatter and forest plots, and funnel plots were used to assess adherence to Mendel's second law. Meanwhile, reliability and robustness were evaluated through heterogeneity tests (P>0.05), horizontal pleiotropy tests (P>0.05), and leave‐one‐out sensitivity analyses. Additionally, the Steiger directionality test was conducted using the directionality_test function to confirm the causal relationship between the candidate genes and HCM, with a correct direction of causality=TRUE and P<0.05 indicating a unidirectional causal relationship. Candidate genes with a significant causal correlation with HCM through these analyses were subsequently designated as candidate feature genes. Identification of Biomarkers Through Machine Learning, Expression Validation, and Receiver Operating Characteristic (ROC) Analysis In the GSE36961 data set, 11 machine‐learning algorithms were applied to generate 101 algorithmic combinations. The algorithms included random forest, Least Absolute Shrinkage and Selection Operator, ridge regression, elastic net, stepwise generalized linear model, support vector machine, glmboost, linear discriminant analysis, gradient boosting machine, eXtreme gradient boosting, and naïve Bayes. Candidate feature genes were used to train diagnostic models across all 101 algorithm combinations with 10‐fold cross‐validation in GSE36961. The performance of each of the 101 algorithmic models was evaluated by calculating the area under the curve (AUC) in both GSE36961 and GSE141910. The optimal combined model was defined as one with an AUC ≥0.7 in both data sets and possessing the highest average AUC. Genes derived from this optimal combination model were designated as feature genes. For GSE36961 and GSE141910, the ROC curves were plotted using the pROC package (v1.18.0) 33 to assess the diagnostic value of the optimal model. Additionally, the expression levels of feature genes between HCM and control groups in the GSE36961 and GSE141910 data sets were compared using the Wilcoxon rank‐sum test through the rstatix package (v0.7.2). 34 Feature genes that exhibited significant intergroup‐differential expression (P<0.05) and consistent expression trends across both data sets were defined as candidate biomarkers. The diagnostic value of these candidate biomarkers for HCM was further evaluated using ROC analysis with the pROC package (v1.18.0), and candidate biomarkers with an AUC ≥0.7 in both GSE36961 and GSE141910 were defined as biomarkers. Subsequently, expression trends and ROC analyses for the validated biomarkers were further examined in data sets GSE130036, GSE160997, and GSE32453. Construction and Assessment of the Artificial Neural Network (ANN) Model To further evaluate the predictive ability of biomarkers for HCM, an ANN model was constructed using the neuralnet package (v1.44.2) 35 in the GSE36961 data set. The biomarker expression data were first preprocessed and normalized. Min–max scaling was applied to transform the data into the [0,1] range before training the neural network. Before calculation, the data values were standardized by determining their maximum and minimum values, and the number of hidden layers was established as 3. While there were no fixed rules for determining the number of hidden layers and neurons, the number of neurons in each hidden layer was constrained to fall between the sizes of the input and output layers, and 3 neurons were selected for the ANN model. Subsequently, a confusion matrix was generated using GSE36961 and GSE141910 to assess the predictive accuracy of the ANN model. In parallel, the diagnostic capability of the ANN model for HCM was assessed using ROC curves generated with the pROC package (v1.18.0) in both GSE36961 and GSE141910, and the AUC was calculated to quantify the predictive performance of the model. An AUC greater than 0.7 indicates a favorable predictive ability. scRNA‐Seq Data Processing The 10× scRNA‐seq data set GSE174691 was processed for quality control (QC) using the Seurat package (v4.1.0). 36 This data set includes nine patient samples, and detailed patient characteristics, including age and sex, are provided in Table S2. Notably, this data set lacked single‐cell samples from normal controls, which is an inherent limitation of the data. 37 , 38 Cells with 200 genes and genes covered in 3 cells were excluded from subsequent analyses. Furthermore, the percentage of mitochondrial gene expression (percent.mt) was calculated using the PercentageFeatureSet function. Before QC, the distribution of nFeature_RNA (number of detected genes), nCount_RNA (total RNA counts per cell), and percent.mt were visualized as violin plots using the VlnPlot function. Subsequently, QC of scRNA‐seq data was performed with the following criteria: 2000.15. Of these, 21 candidate genes with known interactions formed a network comprising 22 edges (Figure 2D). Within this network, SEC61A1, SOCS2, and XBP1 showed multiple interactions with other candidate genes. The remaining 13 candidate genes had no reported interactions at the selected confidence threshold and were therefore excluded from the network. Identification of 34 candidate genes and exploration of their functions. A, Candidate gene identification. B, Circle plots of Gene Ontology (GO) enrichment results for candidate genes. C, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment results and chord diagrams of candidate genes. D, Protein–protein interaction plot of candidate genes. DEGs indicates differentially expressed genes. Identification of 8 Candidate Feature Genes through MR Analysis MR analysis was performed using 34 candidate genes as exposure factors and HCM as the outcome variable. Based on the inverse variance weighted method, 14 genes were identified as significantly associated with HCM (P<0.05) (Table 1), of which 6 were protective factors (OR<1, eg, HBEGF and VPS8) and 8 were risk factors (OR>1, eg, PAFAH2 and CDC42EP2). The MR analysis yielded robust causal estimates, as illustrated by scatter plots showing individual SNP effects (Figure 3A) and forest plots showing the overall causal estimates (Figure 3B). Funnel plots showed symmetrical SNP distributions, supporting the validity of the MR analysis (Figure 3C). Sensitivity analyses further refined the candidate set. Cochran's Q test revealed heterogeneity for CDC42EP2 (P < 0.05), leaving 13 genes without significant heterogeneity (Table 2). The horizontal pleiotropy test excluded 5 genes (MYH7B, KLHL24, PAFAH2, CDC42EP2, and B4GALT5) due to significant pleiotropy (P<0.05), resulting in 9 genes with no evidence of horizontal pleiotropy (Table 3). Leave‐one‐out analysis confirmed the robustness of the results, as no single SNP disproportionately influenced the overall estimates (Figure 3D). The Steiger directionality test further confirmed unidirectional causal relationships for 8 genes (correct_causal_direction=TRUE, P<0.05), while XBP1 was excluded due to an indeterminate result (Table 4). Collectively, the 8 genes that passed all sensitivity analyses—WDR62, PLA2G15, HBEGF, MFN2, AZIN1, VPS8, SLMAP, and RNF103—were designated as candidate feature genes. Table 1Mendelian randomization (MR) estimates for the causal effects of candidate genes on Hypertrophic cardiomyopathy (HCM)id.exposureid.outcomeOutcomeExposureMethodnsnp b SEpvallo_ciup_cioror_lci95or_uci95SYMBOLENSEMBLeqtl‐a‐ENSG00000075702ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000075702Inverse variance weighted100.31030.12675350.01436280.06186310.5587371.36383431.06381671.7484627WDR62ENSG00000075702eqtl‐a‐ENSG00000078814ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000078814Inverse variance weighted1040.31218580.04929852.41E‐100.21556070.4088111.36640861.24055731.5050272MYH7BENSG00000078814eqtl‐a‐ENSG00000100219ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000100219Inverse variance weighted165−0.0624950.01218882.94E‐07−0.086385−0.0386050.9394180.91724120.9621311XBP1ENSG00000100219eqtl‐a‐ENSG00000103066ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000103066Inverse variance weighted590.6439210.08353061.27E‐140.48020110.80764091.90393151.61639942.2426112PLA2G15ENSG00000103066eqtl‐a‐ENSG00000113070ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000113070Inverse variance weighted33−0.4464270.10683242.93E‐05−0.655818−0.2370350.63991080.51901730.7889637HBEGFENSG00000113070eqtl‐a‐ENSG00000114796ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000114796Inverse variance weighted480.3048060.03847582.34E‐150.22939340.38021861.35636181.25783671.4626042KLHL24ENSG00000114796eqtl‐a‐ENSG00000116688ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000116688Inverse variance weighted69−0.1232010.01592871.04E‐14−0.154421−0.091980.88408630.85691130.9121231MFN2ENSG00000116688eqtl‐a‐ENSG00000149798ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000149798Inverse variance weighted540.25699640.07062120.00027360.11857890.39541391.29304051.12589571.4849987CDC42EP2ENSG00000149798eqtl‐a‐ENSG00000155096ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000155096Inverse variance weighted31−0.0993180.03796790.0089007−0.173735−0.0249010.90545470.84051950.9754064AZIN1ENSG00000155096eqtl‐a‐ENSG00000156931ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000156931Inverse variance weighted86−0.1203720.02923753.84E‐05−0.177678−0.0630670.88659020.8372120.9388808VPS8ENSG00000156931eqtl‐a‐ENSG00000158006ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000158006Inverse variance weighted660.18327460.03725758.69E‐070.11024990.25629931.20114421.1165571.2921394PAFAH2ENSG00000158006eqtl‐a‐ENSG00000158470ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000158470Inverse variance weighted32−0.3870090.09452644.24E‐05−0.57228−0.2017370.67908530.56423730.81731B4GALT5ENSG00000158470eqtl‐a‐ENSG00000163681ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000163681Inverse variance weighted520.364830.07031392.12E‐070.22701490.50264521.44026921.25484851.6530882SLMAPENSG00000163681eqtl‐a‐ENSG00000239305ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000239305Inverse variance weighted420.47686770.07512632.19E‐100.32962010.62411531.61102031.39043981.8665939RNF103ENSG00000239305The inverse variance weighted method was used as the primary analysis. b represents the estimated effect size (log odds ratio); se, standard error; Pval, P value; lo_ci and up_ci, lower and upper bounds of the 95% CI for b; or_lci95 and or_uci95, lower and upper bounds of the 95% CI for the odds ratio.ENSEMBL indicates Ensembl gene identifier; OR, odds ratio; and SYMBOL, gene symbol. Mendelian randomization (MR) estimates for the causal effects of candidate genes on Hypertrophic cardiomyopathy (HCM) The inverse variance weighted method was used as the primary analysis. b represents the estimated effect size (log odds ratio); se, standard error; Pval, P value; lo_ci and up_ci, lower and upper bounds of the 95% CI for b; or_lci95 and or_uci95, lower and upper bounds of the 95% CI for the odds ratio.ENSEMBL indicates Ensembl gene identifier; OR, odds ratio; and SYMBOL, gene symbol. Mendelian randomization (MR) analysis identifies candidate feature genes associated with HCM. A, Scatter plots illustrating the causal effects of individual single‐nucleotide polymorphisms (SNPs) on HCM. B, Forest plots display the overall causal estimates from the inverse variance weighted method for each candidate feature gene. C, Funnel plots show symmetrical distribution of SNPs, supporting the validity of the MR analysis. D, Leave‐one‐out sensitivity analysis demonstrates that no single SNP disproportionately influences the overall MR estimate. Table 2Heterogeneity tests for instrumental variables (IVs) in MR analysisid.exposureid.outcomeOutcomeExposureMethodQQ_dfQ_pvalSYMBOLENSEMBL1eqtl‐a‐ENSG00000075702ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000075702Inverse variance weighted4.148651790.9013589WDR62ENSG000000757022eqtl‐a‐ENSG00000078814ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000078814Inverse variance weighted93.8167861030.730085MYH7BENSG000000788143eqtl‐a‐ENSG00000100219ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000100219Inverse variance weighted63.0299841641XBP1ENSG000001002194eqtl‐a‐ENSG00000103066ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000103066Inverse variance weighted24.773409580.9999607PLA2G15ENSG000001030665eqtl‐a‐ENSG00000113070ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000113070Inverse variance weighted15.045177320.9952626HBEGFENSG000001130706eqtl‐a‐ENSG00000114796ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000114796Inverse variance weighted48.010171470.4316548KLHL24ENSG000001147967eqtl‐a‐ENSG00000116688ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000116688Inverse variance weighted65.843425680.5515421MFN2ENSG000001166888eqtl‐a‐ENSG00000149798ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000149798Inverse variance weighted71.217295530.0481812CDC42EP2ENSG000001497989eqtl‐a‐ENSG00000155096ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000155096Inverse variance weighted7.1241553300.9999948AZIN1ENSG0000015509610eqtl‐a‐ENSG00000156931ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000156931Inverse variance weighted70.745825850.8663327VPS8ENSG0000015693111eqtl‐a‐ENSG00000158006ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000158006Inverse variance weighted61.930927650.5850332PAFAH2ENSG0000015800612eqtl‐a‐ENSG00000158470ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000158470Inverse variance weighted26.898423310.6772661B4GALT5ENSG0000015847013eqtl‐a‐ENSG00000163681ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000163681Inverse variance weighted31.138122510.9872554SLMAPENSG0000016368114eqtl‐a‐ENSG00000239305ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000239305Inverse variance weighted8.56499411RNF103ENSG00000239305Q indicates Cochran's Q statistic for heterogeneity; Q_df, degrees of freedom for the Q statistic; and Q_pval, P value for the Q statistic (values >0.05 indicate no significant heterogeneity). Heterogeneity tests for instrumental variables (IVs) in MR analysis Q indicates Cochran's Q statistic for heterogeneity; Q_df, degrees of freedom for the Q statistic; and Q_pval, P value for the Q statistic (values >0.05 indicate no significant heterogeneity). Table 3Horizontal pleiotropy tests using the MR‐Egger methodid.exposureid.outcomeOutcomeExposureegger_interceptSEpvalSYMBOLENSEMBL1eqtl‐a‐ENSG00000075702ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG000000757020.3377129060.2403251260.197574532WDR62ENSG000000757022eqtl‐a‐ENSG00000078814ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000078814−0.0531003260.0229106690.022462184MYH7BENSG000000788143eqtl‐a‐ENSG00000100219ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000100219−0.0046182790.0145682740.751642172XBP1ENSG000001002194eqtl‐a‐ENSG00000103066ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000103066−0.0110421710.0492286530.823323059PLA2G15ENSG000001030665eqtl‐a‐ENSG00000113070ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG000001130700.0187272050.0449557420.679863433HBEGFENSG000001130706eqtl‐a‐ENSG00000114796ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG000001147960.0671354970.0296822930.02847977KLHL24ENSG000001147967eqtl‐a‐ENSG00000116688ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000116688−0.0010580940.0161504340.947959119MFN2ENSG000001166888eqtl‐a‐ENSG00000155096ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG000001550960.0530970460.0333354760.122045888AZIN1ENSG000001550969eqtl‐a‐ENSG00000156931ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG000001569310.0197839820.0154011090.202469816VPS8ENSG0000015693110eqtl‐a‐ENSG00000158006ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000158006−0.0448757010.0165983950.00877508PAFAH2ENSG0000015800611eqtl‐a‐ENSG00000158470ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG000001584700.1122239820.0410932020.010471987B4GALT5ENSG0000015847012eqtl‐a‐ENSG00000163681ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000163681−0.051529550.0292556730.084292802SLMAPENSG0000016368113eqtl‐a‐ENSG00000239305ebi‐a‐GCST90018861Hypertrophic cardiomyopathy || id:ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000239305−0.0363700460.0339805260.290891334RNF103ENSG00000239305egger_intercept, the intercept term from the MR‐Egger regression (a non‐zero intercept indicates directional horizontal pleiotropy); SE, standard error of the intercept; Pval, P value for the intercept (values >0.05 indicate no significant horizontal pleiotropy). Horizontal pleiotropy tests using the MR‐Egger method egger_intercept, the intercept term from the MR‐Egger regression (a non‐zero intercept indicates directional horizontal pleiotropy); SE, standard error of the intercept; Pval, P value for the intercept (values >0.05 indicate no significant horizontal pleiotropy). Table 4Steiger Directionality Test for Causal Direction Between Candidate Gene Expression and HCMid.exposureid.outcomeExposureOutcomesnp_r2.exposuresnp_r2.outcomecorrect_causal_directionsteiger_pvalSYMBOLENSEMBL1eqtl‐a‐ENSG00000075702ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000075702Hypertrophic cardiomyopathy || id:ebi‐a‐GCST900188610.0620429922.07E‐05TRUE1.30E‐189WDR62ENSG000000757022eqtl‐a‐ENSG00000100219ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000100219Hypertrophic cardiomyopathy || id:ebi‐a‐GCST900188612.8630030940.000182376TRUENAXBP1ENSG000001002193eqtl‐a‐ENSG00000103066ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000103066Hypertrophic cardiomyopathy || id:ebi‐a‐GCST900188610.1041321510.000171906TRUE0PLA2G15ENSG000001030664eqtl‐a‐ENSG00000113070ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000113070Hypertrophic cardiomyopathy || id:ebi‐a‐GCST900188610.0494040886.64E‐05TRUE8.29E‐301HBEGFENSG000001130705eqtl‐a‐ENSG00000116688ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000116688Hypertrophic cardiomyopathy || id:ebi‐a‐GCST900188610.8849065620.000256753TRUE0MFN2ENSG000001166886eqtl‐a‐ENSG00000155096ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000155096Hypertrophic cardiomyopathy || id:ebi‐a‐GCST900188610.3740948922.85E‐05TRUE0AZIN1ENSG000001550967eqtl‐a‐ENSG00000156931ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000156931Hypertrophic cardiomyopathy || id:ebi‐a‐GCST900188610.8712909960.0001798TRUE0VPS8ENSG000001569318eqtl‐a‐ENSG00000163681ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000163681Hypertrophic cardiomyopathy || id:ebi‐a‐GCST900188610.1131324170.000118549TRUE0SLMAPENSG000001636819eqtl‐a‐ENSG00000239305ebi‐a‐GCST90018861|| id:eqtl‐a‐ENSG00000239305Hypertrophic cardiomyopathy || id:ebi‐a‐GCST900188610.1174784099.98E‐05TRUE0RNF103ENSG00000239305snp_r2.exposure, the proportion of variance in the exposure (gene expression) explained by the IVs (R2); snp_r2.outcome, the proportion of variance in the outcome (HCM) explained by the IVs; correct_causal_direction, logical indicator (TRUE/FALSE) of whether the assumed causal direction (gene expression→HCM) is correct according to the Steiger test; steiger_pval, P value from the Steiger test (values <0.05 indicate the causal direction is correctly specified). Steiger Directionality Test for Causal Direction Between Candidate Gene Expression and HCM snp_r2.exposure, the proportion of variance in the exposure (gene expression) explained by the IVs (R2); snp_r2.outcome, the proportion of variance in the outcome (HCM) explained by the IVs; correct_causal_direction, logical indicator (TRUE/FALSE) of whether the assumed causal direction (gene expression→HCM) is correct according to the Steiger test; steiger_pval, P value from the Steiger test (values <0.05 indicate the causal direction is correctly specified). HBEGF and VPS8 Were Identified as Biomarkers with Diagnostic Potential To further identify biomarkers associated with HCM and centrosome duplication, the 8 candidate feature genes were incorporated into an integrative machine‐learning model. Across 101 predictive model combinations in GSE36961 and GSE141910, the Lasso+glmBoost model emerged as the optimal combined model, achieving an average AUC of 0.868 in both data sets (Figure 4A). This model identified WDR62, PLA2G15, HBEGF, MFN2, AZIN1, VPS8, and RNF103 as feature genes, while SLMAP was not included. Specifically, the AUC values of the Lasso+glmBoost model in the ROC curve were 0.9821 (95% CI: 0.9578–0.9971) in GSE36961 and 0.7537 (95% CI: 0.6396–0.8524) in GSE141910 (Figure 4B and 4C). Moreover, the findings revealed a notable elevation in the expression levels of PLA2G15, HBEGF, MFN2, AZIN1, VPS8, and RNF103 in the HCM group (P<0.05), with a consistent pattern of expression observed across GSE36961 and GSE141910 (Figure 4D and 4E). Notably, HBEGF and VPS8 individually showed AUC values greater than 0.7 (Figure 4F and 4G), indicating their satisfactory diagnostic potential for HCM. Validation in additional cohorts confirmed the diagnostic potential of HBEGF and VPS8. In GSE130036, HBEGF expression was significantly higher in the HCM group than in controls (P<0.0001), with an AUC>0.9 (Figure S1A and S1D). In GSE160997, HBEGF showed a non‐significant upward trend in the HCM group, while VPS8 was significantly higher in the HCM group (P<0.05); both achieved AUC>0.7 (Figure S1B and S1E). In the small exploratory cohort GSE32453 (n=13), HBEGF remained significantly higher in the HCM group than in controls (P<0.05), whereas VPS8 showed a non‐significant trend toward higher expression in the HCM group, likely due to limited statistical power; nevertheless, both biomarkers yielded AUC>0.7, though these results warrant cautious interpretation (Figure S1C and S1F). Collectively, these findings suggest that HBEGF and VPS8 exhibit consistent expression patterns and may have diagnostic value across multiple cohorts, warranting further investigation as biomarkers for HCM. Machine learning–based identification of centrosome duplication–related biomarkers in HCM. A, Area under the curve (AUC) values of 101 machine learning prediction models evaluated in the GSE36961 and GSE141910 data sets. B and C, Receiver operating characteristic (ROC) curves of the optimal Lasso+glmBoost model in the training cohort GSE36961 (B) and the validation cohort GSE141910 (C). D and E, Expression levels of feature genes identified by the Lasso+glmBoost model in HCM and control samples from GSE36961 (D) and GSE141910 (E). F and G, ROC curves evaluating the diagnostic performance of HBEGF and VPS8 in GSE36961 (F) and GSE141910 (G). MR indicates Mendelian randomization. ANN Model Shows Favorable Diagnostic Performance for HCM The ANN model was constructed to further evaluate the diagnostic value of biomarkers for HCM. The model comprised one input layer, one hidden layer, and one output layer, as illustrated in Figure 5A. Specifically, the input layer had two neurons, the hidden layer had 3 neurons, and the output layer had two neurons. The confusion matrix indicated that the ANN model achieved high prediction accuracy for both the HCM and control groups in both the GSE36961 and GSE141910 data sets (Figure 5B and 5C). Moreover, the AUC values of the ANN model in GSE36961 and GSE141910 were 0.9320271 and 0.7917384, respectively (Figure 5D and 5E), indicating that the ANN model exhibited favorable diagnostic performance in HCM. Artificial Neural Network (ANN) model architecture and diagnostic performance for HCM. A, Visualization of ANN Models, the leftmost layer is the input layer, the middle layers are the hidden layers, and the rightmost layer is the output layer. B and C, Confusion Matrix Heatmap: The Horizontal Axis Represents True Values, and the Vertical Axis Represents Predicted Values. D and E, ROC curves (Training Set on the Left, Validation Set on the Right). AUC indicates area under the curve. VPS8 Is Highly Expressed in Cardiomyocytes and Dendritic Cells Before QC of the scRNA‐seq data, the data set comprised 241 382 cells and 23 411 genes. After QC, 196783 cells were retained, while the gene count remained at 223411 (Figure S2A and S2B). Following standard data processing, a subset of 2000 highly variable genes was identified (Figure 6A). PCA was performed, and the top 20 statistically significant principal components (P<0.05) were selected for subsequent analysis (Figure 6B). Using uniform manifold approximation and projection clustering, 11 distinct cell clusters were identified (Figure 6C), and the expression patterns of key marker genes for each cell cluster were visualized through bubble plots (Figure S2C). Marker genes for each cell cluster are listed in Table 5. Annotation of cell clusters revealed six cell types, including cardiomyocytes, dendritic cells, endothelial cells, fibroblasts, pericytes, and smooth muscle cells (Figure 6D). uniform manifold approximation and projection and bubble plots showed that VPS8 was highly expressed in cardiomyocytes and dendritic cells (Figure 6E and 6F). Moreover, the results indicated that cardiomyocytes and dendritic cells were involved in regulating centrosome duplication in HCM, thereby identifying them as key cell types. VPS8 was highly expressed in cardiomyocyte and dendritic cell. A, Highly Variable Gene Screening. B, Screenfi Plot of Principal Components. C, Uniform Manifold Approximation and Projection (UMAP) Dimensionality Reduction and Clustering. D, UMAP Diagram for Cell Type Annotation. E and F, UMAP Diagram and Bubble Chart of Key Gene Expression Levels. Table 5Marker Genes Used for Annotation of Distinct Cell Types Identified by Single‐Cell RNA Sequencing (scRNA‐seq)Cell typeCell clustersMarker geneCardiomyocyte0,3,7,8,9MYBPC3, MYH7B, MYH7, TNNT2, ACTC1Dendritic6HLA‐DRB1, ITGAXEndothelial cells4AQP1, PECAM1, VWFFibroblast1,2COL1A1, COL6A3, FBN1, IGF1Pericyte5ABCC9, KCNJ8, NOTCH3, STEAP4Smooth muscle cells10SingleR package (v 1.831) 39 Marker Genes Used for Annotation of Distinct Cell Types Identified by Single‐Cell RNA Sequencing (scRNA‐seq) Validation of VPS8 Expression in H9c2 Cells Western blot analysis confirmed a significant reduction in VPS8 protein levels in H9c2 cells following shRNA‐mediated knockdown (Figure 7A). β‐actin served as an internal control, with no apparent differences among groups, confirming successful VPS8 silencing and providing a reliable basis for subsequent functional assays. Validation and functional analysis of VPS8 in H9c2 cardiomyocytes. A, Western blot analysis of VPS8 protein expression in H9c2 cells transfected with control, Negative control shRNA (sh‐NC), or shRNA targeting VPS8 (sh‐VPS8) plasmids, with β‐Actin as the internal control. B and C, Cell Counting Kit‐8 (CCK‐8) assay performed to measure cell proliferation of H9c2 cells at 24, 48, and 72 hours after transfection, and line charts generated to compare cell viability among groups. D through G, Flow cytometry analysis using Annexin V‐fluorescein isothiocyanate/propidium iodide (PI) dual staining to evaluate apoptotic cell populations in each group, accompanied by a quantitative summary of apoptosis percentages. H through K, Immunofluorescence staining of centrosome‐ and microtubule‐associated proteins, including γ‐tubulin, CEP135, PLK4 and Centrin‐2, showing their cellular distribution in H9c2 cells. L, Western blot detection of the same centrosome‐related proteins to verify their expression patterns at the protein level. VPS8 Knockdown Suppresses Cell Proliferation CCK‐8 assay results indicated that VPS8 knockdown suppressed cell proliferation, with the most notable reduction observed from 24 hours onwards and becoming more pronounced at 48 and 72 hours (Figure 7B). The line graph further illustrates that the viability of cells in the sh‐VPS8 group was consistently lower than that of the control and negative control shRNA groups (Figure 7C), suggesting the role of VPS8 in promoting cell growth. VPS8 Knockdown Promotes Apoptosis Flow cytometry analysis using PI and Annexin V–fluorescein isothiocyanate staining revealed a considerable increase in the proportion of apoptotic cells in the sh‐VPS8 group compared with the control and negative control shRNA groups (Figure 7D through 7F). Quantitative bar charts showed a significant elevation in the apoptosis rate following VPS8 knockdown (Figure 7G), indicating that VPS8 may exert a protective effect against apoptosis. VPS8 Regulates Centrosome Proteins and Microtubule Architecture Immunofluorescence staining revealed that VPS8 knockdown led to marked reductions in centrosomal and microtubule‐associated proteins, including γ‐tubulin, CEP135, Centrin‐2, and PLK4 (Figure 7H through 7K), with particularly notable decreases in γ‐tubulin and PLK4 signals. Western blot analysis supported these findings, showing decreased levels of these proteins in the sh‐VPS8 group compared with the controls, with γ‐tubulin exhibiting the most significant decline (Figure 7L). Collectively, these results suggest that VPS8 may regulate centrosome integrity and microtubule organization by modulating the expression and assembly of key centrosomal proteins, thereby influencing cell cycle progression and structural stability in cardiomyocytes. DISCUSSION This study, focused on the role of CDRGs in HCM, constructed a multilayered chain of evidence spanning transcriptomic analysis, coexpression networks, and causal inference through MR, further integrated through machine learning, single‐cell atlas resolution, and functional validation of a key candidate gene at the cellular level. HCM is an inherited cardiovascular disorder characterized by abnormal thickening of the ventricular wall. Patients are often asymptomatic in the early stages; however, as myocardial fibrosis progresses, heart failure frequently develops, for which pharmacological interventions have limited efficacy. The centrosome, which functions as the microtubule‐organizing center within cells, plays a crucial role in regulating cell division and signaling, and its duplication is closely associated with cardiomyocyte proliferation and maturation. Previous research has indicated that inhibiting centrosome duplication promotes the differentiation of immature cardiomyocytes, whereas the Hippo pathway facilitates cardiomyocyte maturation by regulating centrosome disassembly. 6 These findings suggest that aberrations in centrosome replication may contribute to the transition of myocardial growth from hyperplastic to hypertrophic, thereby influencing the pathogenesis and progression of HCM. Based on this framework, this study systematically analyzed the expression profiles and potential mechanistic roles of CDRGs in HCM. Through differential expression analysis, WGCNA‐based coexpression network construction, MR causal inference, and multimodel integrative screening, HBEGF and VPS8 were identified as two candidate genes with stable diagnostic values across multiple cohorts. WGCNA revealed that modules significantly correlated with CDRG activity scores in HCM samples were enriched in pathways involving ion transmembrane transport, cell junction organization, and phagosome/muscle cell cytoskeleton regulation, suggesting a coupling imbalance between cell structure, membrane transport, metabolism, and immune signaling, which may constitute a molecular hallmark of HCM. By applying stringent criteria for IV selection and controlling for heterogeneity and pleiotropy, MR analysis identified consistent causal links between several genes and HCM risk, reinforcing the causal plausibility of CDRG dysregulation in HCM pathology. Further single‐cell transcriptomic analysis revealed that both HBEGF and VPS8 were upregulated in HCM myocardial tissues but exhibited distinct cell‐type distributions and functional associations. Under physiological homeostasis, heparin‐binding EGF‐like growth factor (HBEGF), as a key ligand of epidermal growth factor receptor (EGFR), can regulate BPs such as cell migration, angiogenesis, and anti‐apoptosis by activating the EGFR/PI3K/Akt and MAPK signaling pathways. 48 , 49 , 50 Its high expression in cardiomyocytes and smooth muscle cells supports normal cardiac development and exerts a fundamental cardioprotective effect by inhibiting cardiomyocyte apoptosis, 51 , 52 , 53 , 54 , 55 , 56 , 57 which is consistent with our MR analysis, which identified HBEGF as a protective genetic factor in HCM. When the myocardium is exposed to pathological stresses, such as sarcomere remodeling and abnormal pressure overload induced by HCM‐associated mutations, the body can initiate an adaptive compensatory response to upregulate HBEGF expression, attempting to further antagonize cardiomyocyte apoptosis, improve myocardial blood supply, and delay fibrosis by enhancing the activity of the EGFR/PI3K/Akt pathway. This regulatory logic is similar to the regulatory mode of the HBEGF/EGFR/PI3K/Akt axis in Tetralogy of Fallot, in which loss‐of‐function mutations in ADAM17 impede the normal shedding of HBEGF, resulting in the failure of effective EGFR activation, which in turn triggers abnormalities in the PI3K/Akt pathway and pathological phenotypes, including cardiomyocyte hypertrophy and disorganized sarcomeres. 58 However, the high HBEGF expression in the myocardial tissues of patients with HCM included in this study likely reflects the middle and advanced stages of the disease. At these stages, the upregulation amplitude of HBEGF may no longer match the extent of myocardial injury due to the long‐term pathological microenvironment, resulting in insufficient activation of its downstream protective pathways. Eventually, even sustained high HBEGF expression cannot reverse established irreversible pathological changes, such as myocardial hypertrophy and diastolic dysfunction, presenting a decompensated state characterized by “compensatory upregulation yet failure to block disease progression.” However, the extent of its enrichment in cardiomyocytes and its direct coupling with the centrosome/microtubule system remain insufficiently characterized, limiting its current feasibility for experimental validation. Conversely, vacuolar protein sorting 8 homolog (VPS8) plays a pivotal role in intracellular trafficking and lysosomal function. As a core subunit of the CORVET complex, VPS8 interacts with the Rab5 homolog Vps21 to precisely regulate the maturation and fusion of early endosomes, thereby maintaining the dynamic equilibrium of the endosomal–lysosomal system. 59 , 60 , 61 , 62 , 63 , 64 , 65 Previous studies have established a close association between lysosomal dysfunction and cardiovascular diseases such as HCM and Fabry disease. In Fabry disease, abnormal accumulation of the substrate Gb3 induces cardiomyocyte inflammation and fibrosis, ultimately leading to left ventricular hypertrophy and cardiac dysfunction. 66 Our finding that VPS8 knockdown impairs cardiomyocyte proliferation, increases apoptosis, and dysregulates centrosomal protein suggests that its functions may extend to maintaining cell cycle progression and cytoskeletal stability. Previous studies have shown a close association between lysosome‐mediated autophagy and HCM. As the core organelle of the autophagic pathway responsible for degrading and recycling damaged or obsolete intracellular components, lysosomes can help cardiomyocytes resist external injuries such as hypoxia and oxidative stress through this process, while autophagy is closely linked to the progression of myocardial hypertrophy in HCM. 67 Therefore, the observed upregulation of VPS8 in HCM tissues may represent a compensatory response of the body to pathological stresses induced by the disease. On the one hand, it can enhance lysosomal function, promoting the efficient degradation of damaged components and nutrient recycling to counteract injuries such as hypoxia and oxidative stress induced by HCM‐causing mutations and antagonizing cardiomyocyte apoptosis. On the other hand, it can maintain cell cycle progression and cytoskeletal stability, ameliorating abnormalities such as impaired cardiomyocyte proliferation and centrosomal protein disorders induced by VPS8 knockdown, thereby delaying the progression of myocardial hypertrophy. However, this protective effect has inherent limits: once the disease reaches a decompensated stage, VPS8 upregulation alone cannot reverse the established pathological myocardial changes. Notably, our experiments confirmed that VPS8 knockdown significantly reduces the expression of γ‐tubulin and PLK4, two key centrosomal proteins. The downregulation of these proteins may regulate the progression of HCM through multiple mechanisms. From a histological perspective, PLK4 deficiency directly impairs centriole duplication, triggering a p53‐dependent cell cycle surveillance mechanism. This mechanism prevents the continuous proliferation of cells with abnormal centriole duplication, ultimately resulting in irreversible cell cycle arrest after several cell divisions. 68 Combined with the cell cycle regulatory principle that the completion of centriole duplication is a critical prerequisite for cells to transition from the G2 phase to the M phase, this arrest manifests as G2/M phase arrest. At this stage, cell division is blocked while intracellular protein synthesis and organelle biogenesis continue. Consequently, cardiomyocytes accumulate contraction‐related proteins and organelles, such as mitochondria, which directly promote cardiomyocyte hypertrophy. However, these hypertrophic cardiomyocytes cannot properly organize myofibrils due to abnormal proliferation, which results in cellular disorganization. For instance, in diabetic cardiomyopathy, abnormal centriole duplication has been implicated as a key molecular mechanism driving cardiomyopathy development through the ANXA11‐mediated mitochondrial dysfunction pathway. 69 γ‐Tubulin is a ubiquitous and highly conserved member of the eukaryotic tubulin family. Studies have shown that targeted regulation of γ‐tubulin‐mediated microtubule network tyrosination and interventions in microtubule network function can improve cardiac function in HCM, providing a novel direction for HCM treatment through modulation of the nonsarcomeric cytoskeleton. 70 , 71 , 72 Although existing studies have not clarified the mechanistic association between γ‐tubulin and HCM, the literature indicates that cardiac myosin‐binding protein C (cMyBP‐C) haploinsufficiency can induce α‐tubulin acetylation and upregulate related heat shock proteins in HCM myocardial tissue, promoting abnormal proliferation of the microtubule network. This alteration of the microtubule network represents a novel pathomechanism for the development of cMyBP‐C haploinsufficiency–mediated HCM. Meanwhile, α‐tubulin can interact with the protein QC system to maintain cardiomyocyte proteostasis, and its abnormal expression and modification can exacerbate HCM‐related proteostasis imbalance. 73 Ultimately, these two factors synergistically exacerbate characteristic pathological phenotypes of HCM, including myocardial hypertrophy and cellular disorganization. This study, integrated with findings from Garmany et al and Liang et al, advances the research framework for understanding HCM pathogenesis and its clinical translation. Garmany et al 74 identified upregulation of the Ras‐MAPK signaling cascade as a key driver of myocardial hypertrophy in HCM through multi‐omics analysis, whereas Liang et al 75 confirmed that heart transplantation and other approaches are effective therapeutic strategies for end‐stage HCM. Conversely, our research focuses on the previously underemphasized centrosome duplication–related pathway, providing unique complementary insights. Through integrated multidatabase analysis and in vitro functional validation, we are the first to identify HBEGF and VPS8 as HCM‐specific diagnostic biomarkers, with their diagnostic efficacy validated across multiple cohorts. Functional experiments revealed that VPS8 regulates cardiomyocyte proliferation, apoptosis, and centrosome integrity by modulating key proteins, including γ‐tubulin. Notably, this mechanism is independent of the Ras‐MAPK pathway reported by Garmany et al, 74 yet it collectively contributes to the pathological progression of HCM. Furthermore, the high expression of VPS8 in cardiomyocytes and dendritic cells suggests a potential association among aberrant centrosome regulation, myocardial dysfunction, and immune modulation, offering a novel target for precise intervention in HCM. This mechanistic insight establishes a translational bridge to the clinical treatment strategies highlighted by Liang et al, 75 further enhancing the feasibility of translating basic HCM research into clinical practice. It is noteworthy that, while this study builds on existing literature, it offers clear, innovative extensions. Garmany et al 76 confirmed the involvement of the Ras‐MAPK pathway in the pathophysiological process of obstructive HCM through multi‐omics analysis; this study further identified HBEGF as a potential upstream regulator of this pathway, addressing a knowledge gap regarding its upstream regulatory mechanisms. Similarly, Liang et al 77 proposed the core hypothesis that immune dysregulation contributes to HCM progression. In this study, we revealed that VPS8‐mediated centrosome activation can regulate the immune system, suggesting a novel pathway through which immune dysregulation may influence HCM pathophysiology. These findings further strengthen the immune‐related hypothesis, providing new experimental evidence for HCM pathogenesis by linking centrosome regulation and immune disorders. The MR analysis revealed that genetically high‐expression variants of VPS8 and HBEGF act as protective factors against HCM (OR<1), reflecting their inherent protective roles in maintaining cardiomyocyte function under physiological homeostasis. This finding is consistent with the phenotypic observation that knockdown of VPS8 in vitro inhibits cardiomyocyte proliferation and promotes apoptosis. Notably, the cardioprotective effect of HBEGF has been confirmed to maintain cardiomyocyte survival by activating the EGFR signaling pathway, 78 whereas dysregulation of VPS8 is potentially associated with the pathological process of myocardial injury. 79 The observed upregulation of these 2 genes in myocardial tissue from patients with HCM may represent a compensatory or adaptive response by the body to counteract the pathological processes of the disease. In the early stages of the heart failure pathological cascade, such compensatory upregulation can effectively antagonize myocardial fibrosis, suppress cardiomyocyte apoptosis, and preserve cardiac function. 80 Based on this, we speculate that the HCM samples in this study may represent a decompensated stage, in which the extent of myocardial injury exceeds the threshold for genetic compensation. Consequently, even sustained high expression of VPS8 and HBEGF cannot reverse established, irreversible pathological changes, such as myocardial hypertrophy and diastolic dysfunction. This spatiotemporal discrepancy between the intrinsic protective potential of these genes and the adaptive responses within the pathological microenvironment underscores the complex regulation of gene function in HCM pathogenesis. Our single‐cell analysis revealed significant upregulation of VPS8 in both cardiomyocytes and dendritic cells. In HCM, cardiomyocytes exhibit characteristic alterations, including hypertrophy, disrupted myosin and calcium cycling, and polyploidization. 1 , 2 , 81 , 82 Conversely, dendritic cells may mediate cardiac immune–inflammatory responses and fibrotic processes through antigen presentation. 83 The high expression of VPS8 in these cell types suggests its potential involvement in HCM pathogenesis through 2 pathways: first, by regulating centrosome duplication and microtubule homeostasis in cardiomyocytes, thereby affecting cell cycle progression and survival; and second, by mediating immune signaling in dendritic cells, potentially promoting inflammation and fibrosis. Based on this cellular localization and mechanistic rationale, VPS8 was prioritized for functional validation. Experimental results showed that VPS8 knockdown significantly inhibited cardiomyocyte proliferation, promoted apoptosis, and reduced the expression of key centrosomal and microtubule‐associated proteins, including γ‐tubulin, CEP135, Centrin‐2, and PLK4, further validating its crucial role in maintaining cardiomyocyte structural homeostasis. Collectively, these findings establish a complete evidence chain—from bioinformatic screening and single‐cell localization to experimental validation—highlighting the central role of VPS8 in HCM pathological remodeling. This study has several methodological limitations, and caution is required when defining its scope of application and interpreting its conclusions. For in vitro functional validation, the H9c2 rat cardiomyoblast cell line was used to examine the biological effects of VPS8. As embryonic‐derived rat cardiac precursor cells that have not undergone terminal differentiation, H9c2 cells differ significantly from mature human cardiomyocytes in gene expression profiles, cellular structures (eg, sarcomere organization), and electrophysiological contractile functions. Additionally, evolutionary species divergence may result in species‐specific regulatory pathways and functional effects of genes, including VPS8. Therefore, extrapolating in vitro experimental results to human HCM pathophysiology should be approached with caution. Due to experimental constraints and ethical considerations, validation was not performed in primary human cardiomyocytes or in mature human cardiomyocytes derived from induced pluripotent stem cells. Future research should use human‐derived cardiomyocyte models to further verify the functions of target genes and enhance the clinical translational value of these findings. Regarding data sources and analyses, the core discoveries of this study were primarily based on secondary analyses of Gene Expression Omnibus data sets. Although multiple independent data sets were used for model training and validation to enhance robustness, these data sets may have inherent demographic imbalances (eg, age and sex) or limited ethnic diversity. Such potential selection bias could limit the generalizability of biomarker models and related conclusions across broader populations. 84 Subsequent studies should validate these findings in larger, prospectively collected, and more ethnically diverse cohorts. Additionally, some validation data sets (eg, GSE141910) showed imbalanced case–control sample sizes. Although robust statistical methods and machine‐learning algorithms, including Least Absolute Shrinkage and Selection Operator with inherent tolerance for imbalance, were applied and cross‐validation was performed to evaluate model performance, sample size disparities may still affect the statistical power of differential expression analyses and model calibration. The convergence of evidence across multiple data sets, however, mitigates the impact of biases in individual data sets. Finally, validation in cohort GSE32453 was limited by its very small sample size (n=13). While the observed trends were consistent with larger cohorts, statistical estimates from such a small sample are inherently unstable and should be interpreted as preliminary or supportive rather than definitive. The primary evidence supporting our conclusions derives from larger, more robust data sets. At the single‐cell level, limitations include the absence of multiple‐testing correction, as the analysis was primarily focused on phenotypic characterization in a relatively small sample. Furthermore, the data set lacked normal control samples, thus limiting the comparative interpretation. Future studies should validate these single‐cell findings in larger cohorts with paired normal and tumor samples. Traditionally, genetic studies of HCM have predominantly focused on sarcomeric genes. Conversely, our multi‐omics framework—encompassing transcriptome‐based coexpression network analysis, MR‐based causal inference, single‐cell resolution localization, and functional validation—highlights a previously underrecognized group of CDRGs as potential contributors to HCM pathogenesis. These findings indicate that the pathological mechanisms of HCM may involve defects in the contractile apparatus and broader dysregulation of cell cycle regulation, intracellular trafficking, and structural maintenance systems. Within this regulatory network, HBEGF and VPS8 emerge as central nodes representing 2 complementary pathological pathways: growth factor–mediated survival signaling and endomembrane system–mediated maintenance of cellular homeostasis, respectively. Their concurrent dysregulation may collectively drive the complex phenotypic manifestations of hypertrophic cardiomyocyte growth, abnormalities in electromechanical coupling, and interstitial fibrosis in HCM. In summary, this study proposes a novel molecular framework in which dysregulation of CDRGs may, through VPS8‐mediated imbalance in vesicular trafficking and the endosomal–lysosomal pathway, disrupt the structural and metabolic homeostasis of cardiomyocytes. This process may act synergistically with immune cell–mediated inflammatory and fibrotic processes, thereby promoting the electromechanical–immune coupled remodeling observed in HCM. The coordinated upregulation of HBEGF and VPS8 reflects the involvement of 2 complementary pathological pathways: growth factor signaling and maintenance of cellular structural homeostasis. Building on the functional validation of VPS8, this study provides new mechanistic insights into HCM pathogenesis and suggests potential translational directions for early diagnosis and targeted therapeutic interventions. Future studies employing cardiomyocyte‐specific conditional knockdown or overexpression of Vps8 in animal models will be essential to further validate its critical role in myocardial hypertrophy and fibrosis at the histological, molecular, and functional levels. Sources of Funding This research was supported by the National Natural Science Foundation of China (Grant No. 82560082) and the Natural Science Foundation of Jiangxi Province (Grant No. 20212BAB206042). Disclosures None. Supporting information Data S1 Supporting Information Tables S1–S4 Figures S1–S2